News

Results from a Novartis Pharmaceuticals Canada study to assess the company’s Ultibro Breezhaler were published in the New England Journal of Medicine.  Researchers say the results are promising and expected to impact the future management and treatment of patients with chronic obstructive pulmonary disease (COPD). An article describing the findings, “…

GlaxoSmithKline and Innoviva announced positive data from the Phase 3 FULFIL clinical trial evaluating their investigational triple combination therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/IV) in patients with chronic obstructive pulmonary disease (COPD). FULFIL is a randomized, double-blind, multicenter study designed to evaluate the efficacy and safety of a daily dose of the FF/UMEC/IV…

Researchers from the University of Texas Medical Branch (UTMB) at Galveston are studying the latest trends for pulmonary rehabilitation (PR) therapy among older adults with chronic obstructive pulmonary disease (COPD). PR therapy is designed as a comprehensive approach to help patients relieve COPD symptoms and flare-ups while teaching them how…

Pulmonary rehabilitation could reduce the frailty of older people with chronic obstructive pulmonary disease (COPD) suggests a new study published in the journal Thorax.

The clinical stage biopharmaceutical Pulmatrix, recently announced the completion of a pilot study to access the pharmacokinetics of PUR0200 for maintenance treatment of bronchospasms in patients with chronic obstructive pulmonary disease (COPD). The testing of PUR0200, a dry powdered generic of a once-daily, long-acting muscarinic antagonist, was done using healthy volunteers. In Europe,…

Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the United States. But while significant scientific progress is being made, COPD patients face serious challenges when it comes to treatment access, particularly because  treatments costs are high and hospitals have not yet reached recommended standards for COPD care. The startling opinions,…

GlaxoSmithKline (GSK) and Innoviva (INVA) recently published promising data about the Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD). The clinical trial demonstrated that Relvar Ellipta (fluticasone furoate and vilanterol) could reduce exacerbations compared to usual care, for people with COPD. Usual care involved long-acting muscarinic antagonists (LAMA), long-acting beta2-agonists…

Verona Pharma plc. a U.K.-based clinical stage pharmaceutical company, recently announced positive results from a phase 2 clinical trial testing their compound RPL554. According to the company, the therapy provides extra dilation of the passageways into the lungs in patients with chronic obstructive pulmonary disease (COPD) used in combination with standard medicines…

During this year’s Respiratory Effectiveness Group (REG) Summit (2016 REG Summit), researchers from around the globe highlighted the urgent need for more research into current therapies for chronic obstructive pulmonary disease (COPD). According to a news release, this concern is in line with the announcement by members of the…

GlaxoSmithKline (GSK) recently presented new data from a pre-specified analysis of the SUMMIT clinical trial, showing that once daily treatment with  Breo Ellipta (fluticasone furoate/vilanterol) reduced exacerbations in chronic obstructive pulmonary disease (COPD) patients compared to placebo. The presentation was one of two given at the American Thoracic Society (ATS) 2016 International…